key: cord-0717102-j3x4r5b6
authors: Antonini, Angelo; Leta, Valentina; Teo, James; Chaudhuri, K. Ray
title: Outcome of Parkinson's Disease Patients Affected by COVID‐19
date: 2020-05-28
journal: Mov Disord
DOI: 10.1002/mds.28104
sha: 2fcb544e6618d3be49fd79a93b61bf755a12647c
doc_id: 717102
cord_uid: j3x4r5b6

nan

There is extensive debate on the neurological consequences of corona virus disease 2019 (COVID-19) and the impact this might have for patients with neurodegenerative conditions, including Parkinson's disease (PD). Older advanced PD patients may represent a particularly vulnerable population, as respiratory muscle rigidity as well as impairment of cough reflex alongside preexisting dyspnoea may lead to increased severity of COVID-19. 1 In addition, there are indirect possible effects, such as the impact of stress, self-isolation, and anxiety, as well as the consequences of prolonged immobility because of the lockdown. 2, 3 Several observations make the link between COVID-19 and PD particularly intriguing. Antibodies against coronavirus were found in the cerebrospinal fluid of PD patients more than 2 decades ago, suggesting a possible role for viral infections in neurodegeneration. 4 Angiotensin-converting enzyme 2 (ACE2) receptors are highly expressed in dopamine neurons, and they are reduced in PD because of the degenerative process; therefore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related brain penetration may cause additional harm and worsen symptoms and may increase the requirement of dopamine replacement therapy, as evident in 5 of our cases. 5, 6 Interestingly, the ability of coronaviruses to enter the brain through the nasal cavity determines anosmia/ hyposmia and ageusia in many infected subjects, a symptomatology that closely resembles one of the most prominent premotor symptom of PD. 7 Finally, the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19, as ACE2 and dopamine decarboxylase coexpress and coregulate in nonneuronal cell types, which may indicate dopamine depletion and the need for considering levodopa as treatment. 8 Outcomes of PD patients infected by SARS-CoV-2 are unknown. We present here the outcome of 10 clinical cases (Table 1 ) collected from the experience at the Parkinson and Movement Disorders Unit in Padua, Italy, and the Parkinson's Foundation Centre of Excellence at King's College Hospital in London, UK, from the beginning of March to the current period. The PD center in Padua has a catchment of 1022 patients, mainly in the province of Padua, which had 3407 cases of COVID-19, 2 of whom were advanced PD patients. Both were women residing in nursing homes with severe motor manifestations, and both were treated with levodopa therapy (Table 1) . One remained asymptomatic, whereas the other, who in the last months had been suffering from deteriorating cognition and hallucinations, developed respiratory problems and died. The King's center has 4000 PD patients in the catchment and is currently following more than 600 patients. In all, thus far, 8 cases have been identified with COVID-19, and clinical details are presented here. The Kings' COVID-19 PD group consists of 6 men and 2 women, all older than 60 years of age with severe motor dysfunction, comorbidities, and most requiring additional levodopa dosing following infection (Table 1) . Anxiety and other nonmotor features, such as fatigue, orthostatic hypotension, cognitive impairment, and psychosis, also worsened during the infection. Fatigue was a dominant symptom during the SARS-CoV-2 infection in all cases on advanced therapies. Three patients died from COVID-19 pneumonia.

These findings suggest that PD patients of older age (mean, 78.3 years) with longer disease duration (mean, 12.7 years) are particularly susceptible to COVID-19 with a substantially high mortality rate (40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem especially vulnerable, and a mortality rate of 50% among our 4 such cases is of concern. Although 2 recent articles have addressed the issue of COVID-19 in PD, none specifically showed cases directly affected by COVID-19, and we believe ours is the first report of this nature. 2, 3 The report of Prasad et al focuses on the perceptions of SARS-CoV-2 infection in 100 PD patients and some symptoms listed tally with our observations in a real-life population with COVID-19. 2 Many national and charity guidelines do not list PD or specifically older subjects on advanced therapies as a susceptible group, and this information needs to be amended in light of these new data. 9 

Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study

Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers

The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities

Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease

Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra

The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease

Prodromal PD: A new nosological entity

An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19

Management of Advanced Therapies in Parkinson's Disease Patients in times of Humanitarian crisis: the COVID-19 experience

SGML and CITI Use Only DO NOT PRINT Author Roles

Angelo Antonini: conception, data collection, manuscript, review and critique. Valentina Leta: data collection, review and critique. James Teo: data collection, review and critique

conception, data collection, manuscript, review and critique. Financial Disclosures of all authors

Horizon 2020 -PD_Pal grant 825785, and Ministry of Education University and Research (MIUR) grant ARS01_01081. He serves as consultant for Boehringer-Ingelheim for legal cases on pathological gambling. Valentina Leta reports grants from BRC, Parkinson's UK, speaker-related activities fees from Britannia Pharmaceuticals, and consultancy fees from Invisio Pharmaceuticals, outside the submitted work. James Teo has received research support and funding from InnovateUK, Bristol-Myers-Squibb, and iRhythm Technologies and holds shares < £5000 in Glaxo Smithkline and Biogen. K. Ray Chaudhuri has received honoraria for advisory board from AbbVie, UCB, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, and Scion; hnoraria for lectures from AbbVie

Acknowledgments: The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. There are no funding sources to disclose. The authors also thank all clinicians and front-line staff engaged in the care of COVID-19 patients at King's College and Princess Royal Hospitals, London, UK, as well as at the Parkinson and Movement Disorders Unit in Padua, Italy.